How FDA decides which generic applications to review first

On Oct. 18, 2006, FDA's Office of Generic Drugs issued an internal manual that modified what it called its "first-in, first-reviewed" approach to generic drug applications. The manual, MAPP 5240.3, has been revised six times since. The current version¹, dated Oct. 5, 2022, lists about a dozen circumstances in which an application can move ahead of the line.

FDA's counts show the effect. Of the 468 generic applications FDA received for review in fiscal 2025, 80 were assigned priority review and 388 standard, according to its performance report to Congress⁴. In fiscal 2024 the split was 171 priority and 541 standard.

Priority decides how soon a cheaper version of a drug can reach pharmacies, particularly for medicines with one or two makers or ones on FDA's shortage list. This piece explains the statutory rule, the manual's factors, the related competitive generic therapy program, and what the numbers show.

What priority buys

A priority application gets one of two things, the manual says. It can get a shorter goal date, or an expedited review, in which FDA "will strive to act on an ANDA as soon as possible, including prior to the goal date if possible," but the goal date itself does not move.

Congress made part of this mandatory in 2017, in section 801 of the FDA Reauthorization Act, according to FDA's quarterly FDARA report⁵. Under 21 U.S.C. 355(j)(11)², FDA "shall prioritize the review of, and act within 8 months of the date of the submission of" an original generic application for a drug with "not more than 3 approved drug products" listed in the Orange Book and no blocking patents or exclusivities, or a drug on the federal shortage list. The catch is paperwork. The applicant must send complete facility information at least 60 days before it files, so FDA can decide early whether an inspection is needed.

The GDUFA III commitment letter³, FDA's user fee agreement with industry, turns that into clocks, each to be met for 90 percent of submissions.

Of 174 priority original applications received in fiscal 2024, FDA had acted on 160 by Sept. 30, 2025, and 96 percent of those actions met the goal, the performance report says. How the standard clocks have fared is covered in GxRadar's piece on ANDA review goal dates.

The factors in the manual

MAPP 5240.3 goes beyond the statute. An applicant must ask, with a cover letter that "clearly states 'Priority Review Requested,'" names the factor and supplies documentation. FDA will assess shortage, public health emergency and statutory-priority cases even without a request. Qualifying under several factors brings no extra benefit, and if one strength qualifies, the whole submission does.

Two limits stand out. Applications tied to factories with an "Official Action Indicated" inspection finding, the most serious outcome described in GxRadar's explainer on FDA inspections, "generally will not be considered for a priority review." And once FDA has assigned a goal date, it "will not shorten the goal date for that submission even if FDA subsequently grants the submission priority review." The decision itself waits until the application is received, which is why the refuse-to-receive check comes first.

Two of the factors tie priority to the patent system described in Paragraph IV certifications and 180-day exclusivity. A footnote in the manual says FDA "will no longer automatically prioritize" every first-day filer, only those that will be ready for final approval at or before the goal date. For first generics generally, FDA's first generics page¹⁰ says the agency "prioritizes review of these submissions."

Shortages and sole sources

Shortage priority depends on the list's status at the moment FDA decides. As of Nov. 3, 2026, FDA's list showed 69 current shortages, and 71 percent of them were injectables, according to GxRadar's analysis of openFDA shortage data¹¹. The median current shortage had been listed for 1,710 days. GxRadar's review of the November 2026 list has the details.

The sole-source factor, added in 2016 according to the manual's change table, covers old drugs where the brand has left and one generic maker remains. Those markets are described in why some generics have only one maker. FDA's Drug Competition Action Plan¹², launched in 2017, is one of the initiatives the manual names as the source of its approach.

Competitive generic therapy, a separate track

Competitive generic therapy designation, created in 2017 under section 506H of the drug law, overlaps with priority without being the same thing. FDA's CGT guidance⁹ (Revision 1, October 2022) says expedited review of a designated drug "does not always result in a shorter GDUFA goal date." An applicant wanting the shorter clock has to qualify under section 505(j)(11) or the manual. GxRadar's CGT explainer covers the designation and its own 180-day exclusivity.

FDA's CGT approvals list⁸, updated Nov. 3, 2026, has 533 entries. By GxRadar's count, 221 include at least one product marked eligible for CGT exclusivity. In fiscal 2025, FDA's April 2026 Office of Generic Drugs presentation¹³ says, 107 approvals or tentative approvals carried CGT designation.

What the quarterly reports show

A 2017 law requires FDA to report each quarter on applications under the eight-month priority provision and on CGT applications. GxRadar totaled the approvals.

At the end of June 2026, 38 statutory-priority applications were awaiting FDA action and 48 were waiting on applicants, the fiscal 2026 report⁵ shows. For CGT applications the figures were 186 and 171. Priority is a small slice of the total. FDA approved 689 generic applications in fiscal 2025, according to its monthly activity report¹⁴.

FDA is cautious about what designation achieves. Of six CGT approvals in fiscal 2026 where it took steps to speed things up, five came after two or fewer review cycles, the report says, but "it is difficult to assess the effect" without a larger sample and a comparison group. Fourth-quarter figures for fiscal 2026, covering July through September, had not been posted as of the page's Aug. 12, 2026, update. New approvals appear on GxRadar's approvals tracker.